drugset / Trial / NCT04468360

Pharmacokinetic Study for IV Allopregnanolone

NCT04468360 ↗

Non-randomizedSequentialOpen-labelOther

Summary

About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but responses vary greatly across individuals and PTSD subpopulations. Neurobiological factors impacted by life experiences, stress, and genetics can affect treatment responses. These factors can alter brain capacities needed to reprocess traumatic memories to prevent them from triggering intense, distressing, disruptive, out-of-place responses. Before starting the interventional study (described in detail in NCT07079761), the investigators will conduct two pharmacokinetic (PK) studies (PK-1 and PK-2) in a small group of individuals with PTSD to test dosing and safety at Boston Medical Center.

Timeline

Start
2022-03-04
Primary completion
2025-04-29
Completion
2025-04-29

Outcome

Outcome not reported

Stopped: “The investigator moved to another institution; only preliminary data from pharmacokinetic studies were collected at Boston University School of Medicine/Boston Medical Center.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Allopregnanolone Small molecule 2.6 ug/kg Intravenous
Subject Allopregnanolone Small molecule 28 ug/kg Intravenous